A clinical role for metabolic inhibition is also well established, with targeting of mammalian target of rapamycin (mTOR), which integrates cues for T cell activation, differentiation, and function (14), used for both GVHD prophylaxis and treatment (15). Here, MTOR is linked to graft versus host disease.